John A. Stalfort III - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director
Signature: /s/ Katherine Denby, Attorney-in-Fact
Stock symbol: ABOS
Transactions as of: Jul 6, 2021
Transactions value $: $560,000
Form type: 4
Date filed: 7/8/2021, 06:17 PM
Previous filing: Jul 2, 2021
Next filing: Jun 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+130K	+1822.23%		137K	Jul 6, 2021	Direct	F1
transaction	ABOS	Common Stock	Purchase	$560K	+35K	+25.49%	$16.00	172K	Jul 6, 2021	Direct
transaction	ABOS	Common Stock	Conversion of derivative security		+132K			132K	Jul 6, 2021	See footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A-1 Preferred	Conversion of derivative security	$0	-130K	-100%	$0.00^*	0	Jul 6, 2021	Common Stock	130K		Direct	F1
transaction	ABOS	Series B Preferred	Conversion of derivative security	$0	-132K	-100%	$0.00^*	0	Jul 6, 2021	Common Stock	132K		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.